Veracyte acquires Convergent Genomics for up to $180m
Veracyte has agreed to acquire Convergent Genomics, adding the UroAmp urinary tumour DNA (utDNA) testing platform to its growing urology diagnostics portfolio. The deal, announced on 14 September 2026, carries $150 million in upfront cash consideration and up to $30 million in additional payments tied to reimbursement milestones for UroAmp, bringing the total potential consideration to $180 million.
UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), a disease subset representing roughly 600,000 of the estimated 750,000 people currently living with bladder cancer in the United States. The platform analyses urinary tumour DNA rather than circulating tumour DNA from blood, a distinction that matters in NMIBC because the disease is typically confined to the bladder wall and may shed insufficient DNA into the bloodstream for reliable blood-based detection.
Clinical evidence and near-term launch plans
The acquisition comes with a meaningful body of evidence. UroAmp is supported by nine peer-reviewed publications and more than 40 posters and abstracts. Headline data from the RUMBLE study, published in The Journal of Urology, illustrate the platform's potential: patients who tested utDNA-positive after completing BCG induction therapy had a 12-month recurrence-free survival rate of just 25%, compared with 91% among those who tested negative. That 66-percentage-point spread suggests real clinical utility in risk-stratifying patients at a decision point where clinicians currently have limited molecular guidance.
Veracyte intends to commercialise its first UroAmp-based test in late 2028, subject to reimbursement timelines. The initial indication will centre on predicting which patients who have completed BCG induction therapy are likely to benefit from maintenance treatment. The company also plans to extend the platform to intravesical maintenance therapy monitoring and surveillance following curative-intent treatment.
Marc Stapley, Veracyte's chief executive, said UroAmp "brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease" and described the acquisition as completing a multimodal approach across urine, tissue, and blood. The company already markets Decipher Bladder, a tissue-based genomic classifier, and TrueMRD, a minimal residual disease monitoring test for muscle-invasive bladder cancer.
Market context and competitive positioning
The bladder cancer diagnostics market is becoming increasingly contested. Urine-based approaches have attracted interest for several years, partly because of the biological rationale Veracyte cites, and partly because repeat cystoscopy, the current surveillance standard, is invasive and costly. A number of academic centres and early-stage companies have been developing utDNA and urine biomarker panels, making Convergent Genomics' peer-reviewed publication record and CLIA-certified laboratory in South San Francisco operationally valuable assets for Veracyte to absorb.
For Veracyte, the acquisition is consistent with a broader strategy of building a multimodal, indication-specific diagnostics portfolio rather than pursuing a single technology across many tumour types. The company's existing bladder tests target distinct clinical questions, and UroAmp fills a surveillance and therapy-monitoring gap that neither Decipher Bladder nor TrueMRD currently addresses. Investors will note that Veracyte has left its 2026 adjusted EBITDA guidance unchanged, absorbing Convergent's operating expenses within existing guidance rather than flagging a material near-term financial impact.
The 2028 commercialisation timeline is contingent on reimbursement coverage, which remains the central execution risk. Without a favourable coding and coverage decision from CMS, the commercial launch could be delayed. Veracyte has experience navigating that process with its existing tests, and the RUMBLE data should support a dossier submission, but the reimbursement pathway for novel liquid biopsy tests in urology has historically been protracted.